Journal of Surgery and Medicine -ISSN=2602-2079

Prevalence and antibiotic resistance of bacterial pathogens in respiratory tract samples of geriatric patients

Meryem Çolak, Elçin Kal Çakmaklıoğulları

Department of Medical Microbiology, Faculty of Medicine, Karabuk University, Karabuk, Turkey

> ORCID ID of the author(s) MÇ: 0000-0001-9876-935X EKÇ: 0000-0002-2497-207X

Corresponding Author

Meryem Çolak Karabuk University, Faculty of Medicine, Department of Medical Microbiology, Karabuk, Turkey E-mail: meryemcolak@karabuk.edu.tr

Ethics Committee Approval The ethics approval was obtained from the Non-Interventional Clinical Research Ethics

Committee of Karabuk University; No: 2021/452. All procedures in this study involving human participants were performed in accordance with the 1964 Helsinki Declaration and its later amendments.

Conflict of Interest No conflict of interest was declared by the authors.

Financial Disclosure The authors declared that this study has received no financial support.

> Published 2021 May 15

Copyright © 2021 The Author(s) Published by JOSAM This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NDBerviatives License 4.0 (CC BY-NC-ND 4.0) where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.



Abstract

Background/Aim: The frequency and severity of respiratory tract infections increase with aging. The aim of this study was to determine the bacterial profile of respiratory tract samples in geriatric patients and evaluate the antibiotic susceptibility patterns of the pathogens.

Methods: In this cross-sectional study, a total of 509 clinical samples which were obtained from 302 geriatric patients over 65 years of age and sent to the microbiology laboratory between June 2019-January 2021 were investigated retrospectively. The identification and antibiotic susceptibilities of strains were evaluated with BD-Phoenix-100 fully automated microbiology system.

Results: Of the 302 geriatric patients, 166 (%55) were males and 136 (%45) were females. The most isolated pathogens were *Klebsiella pneumoniae* (25.3%) *Pseudomonas aeruginosa* (22.5%) and *Acinetobacter baumannii* (10.2%), *Corynebacterium striatum* (7.3%), *Escherichia coli* (6.4%), *Staphylococcus aureus* (6.4%) and coagulase-negative staphylococci (4.2%). The production of ESBL in *Klebsiella pneumoniae* strains (52.3%) was higher than in *Escherichia coli* (41%) strains. All *Corynebacterium striatum* samples were resistant to ciprofloxacin, tetracycline, rifampin, and penicillin. Methicillin resistance among *Staphylococcus aureus* (MRSA) isolates was 22.7% and they were 100% susceptible to vancomycin and teicoplanin. Above 90% of *K. pneumoniae*, *P. aeruginosa* and *A. baumannii* positive patients were hospitalized in intensive care units (P<0.05). The tobramycin-resistant *E. coli* and colistin-resistant A. *baumannii* rates were highest between 85-99 years of age (P<0.05).

Conclusion: K. *pneumoniae*, *P. aeruginosa* and *A. baumannii* were the most common pathogens in respiratory tract samples in geriatric patients, especially those hospitalized in the intensive care units. The antimicrobial resistance rates were higher in patients aged \geq 85 years. Vancomycin and teicoplanin were the most effective antibiotics against MRSA. It is thought that the results will be useful in the preparation of treatment protocols and guiding physicians about the correct use of antibiotics.

Keywords: Antibiotic resistance, Geriatric patients, Respiratory tract samples

Introduction

The World Health Organization has determined the age of 65 and above as 'old age' and, the United Nations has agreed that 60+ years may be denoted as 'old age' [1]. Elderly people are more susceptible to disease, syndromes, injuries, and sickness than adults. In addition, the atypical symptoms pose a diagnostic challenge in the elderly [2].

Respiratory tract infections are the most common cause of antibiotic use and the main causes of morbidity and mortality worldwide. The frequency and severity of respiratory tract infections increase with aging. Respiratory tract infections and pneumoniae accounted for nearly half of all infection-related hospitalizations in elderly individuals [3]. Many different groups of microorganisms can cause respiratory tract infections. The most common causative bacteria are Streptococcus pneumoniae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pyogenes [4, 5]. Also, extended spectrum beta-lactamase (ESBL) producing and carbapenem-resistant Enterobacterales, methicillin-resistant **Staphylococcus** aureus (MRSA), vancomycin-resistant enterococci species and multi-drugresistant Acinetobacter baumannii are associated with both nosocomial and community-acquired infections. Multidrugresistant Acinetobacter baumannii, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa and Enterobacter species have become major concerns at hospital settings worldwide [5, 6].

Determining of the common pathogens that cause such infections and the patterns of resistance to existing antimicrobial drugs is crucial for defining therapeutic strategies. Bacterial pathogens responsible for respiratory tract infections and antibiotic resistance may vary by country, regions of the country, hospital, clinics and even clinic wards. Therefore, local surveillance data are required, which include detailed analysis of etiological factors [7].

The aim of this study was to determine the etiological agents causing respiratory tract infections in geriatric patients and evaluate the antibiotic susceptibility patterns of the pathogens, which would provide information to optimize accurate timely diagnosis, and treatment of the elderly patients.

Materials and methods

In this study, 509 respiratory tract samples obtained from 302 geriatric patients over 65 years of age and sent to the microbiology laboratory from various clinics such as the Intensive Care Unit, Chest Diseases, Internal Medicine, Palliative Care, Cardiology, Medical Oncology, General Surgery, Neurology, etc. in Karabuk University Training and Research Hospital between June 2019-January 2021 were investigated retrospectively. The other clinical samples test results, repeated patient results and the patients <65 years of age were excluded from this study. These results were obtained from the laboratory information system.

Clinical samples, including endotracheal aspirate (ETA), sputum, and bronchoalveolar lavage (BAL) were cultured on 5% sheep blood agar (RTA laboratories, Kocaeli, Turkey), Eosin Methylene Blue agar (EMB) (RTA), and

Chocolate Agar (RTA) and incubated aerobically at 37°C for 24-48 hours.

The identification and antibiotic susceptibility of strains were determined with the BD/Phoenix-100 (Becton Dickinson, USA) automated system. Antibiotic susceptibility test results were evaluated as per EUCAST (The European Committee on Antimicrobial Susceptibility Testing) guidelines and the production of the ESBL (extended spectrum beta lactamase) enzyme was determined using the combined disk diffusion method [8]. The *E. coli* ATCC 25922, *S. aureus* ATCC 25923, and *P. aeruginosa* ATCC 27853 were used as quality control strains.

Statistical analysis

Data were analyzed using Statistical Package for the Social Sciences (SPSS for IBM-PC 20.0; SPSS Inc., USA). Descriptive statistics were stated as number (n), percentage (%), and median value. The Kolmogorov–Smirnov test was used to determine whether the variables were normally distributed. For the comparison of continuous variables, the two-sample t-test was used. The Pearson's Chi-squared test or Fisher's Exact test was used for comparison of categorical variables if applicable. A probability (P) value of <0.05 was considered statistically significant at 95% confidence interval.

Results

A total of 302 geriatric patients comprising 166 (%55) males and 136 (%45) females were included in the study. All the patients were >65 years of age and the median age of the patients was 79 (65-99) years.

In our study, 302 outpatients and inpatients were investigated, 84.4% (255/302) of which were hospitalized in the Intensive Care Unit, 7.9% (24/302), in Chest Diseases, 2.6% (8/302), in Internal Medicine, 2.3% (7/302), in Palliative Care, and 26 % (8/302) in Cardiology, Medical Oncology, General Surgery, Neurology, etc. A total of 509 clinical samples were examined, including 80% (410/509) endotracheal aspirates (ETA), 11% (53/509) sputum samples, 9% (46/509) bronchoalveolar lavage (BAL).

In 500 (98%) of 509 samples, pathogenic microorganisms were detected. No growth was observed in 9 samples (1.8%). Most isolated pathogens were Gram negative bacteria (68%, n=339), and the rate of Gram-positive bacteria was lower (20%, n=102). In the present study, 35 different pathogenic bacteria were isolated, and more than one microorganism growth was detected in 82 (27.1%) patients. The most isolated pathogens were Klebsiella pneumoniae (25.3%) Pseudomonas aeruginosa (22.5%) and Acinetobacter baumannii (10.2%), Corynebacterium striatum (7.3%), Escherichia coli (6.4%), Staphylococcus aureus (6.4%) and coagulase- negative staphylococci (CNS) (4.2%). The prevalence and distribution of the samples according to the isolated pathogens is shown in Table 1.

K. pneumoniae, *P. aeruginosa* and *A. baumannii* positivity were 93.4%, 92.9% and 90%, respectively, among patients hospitalized in the Intensive Care Units. The distribution of *K. pneumoniae*, *P. aeruginosa* and *A. baumannii* positivity was examined according to clinics, which revealed that above

90% of positive patients were hospitalized in the intensive care units (P < 0.05).

Table 1: The distribution of the samples according to the isolated pathogens

Table 1. The distribution of the samples according to the isolated pathogens								
Pathogens	ETA		Sputum		BAL		TOTAL	
	n	%	n	%	n	%	n	%
Klebsiella pneumoniae	116	91.5	6	4.4	5	4.1	127	25.3
Pseudomonas aeruginosa	94	84	9	7.7	9	8.3	112	22.5
Acinetobacter baumannii	41	79.7	3	6.8	7	13.4	51	10.2
Corynebacterium striatum	34	94.1	1	1.3	2	4.6	37	7.3
Escherichia coli	21	67.1	8	24.9	3	8	32	6.4
Staphyloccocus aureus	30	92.4	-	-	2	7.6	32	6.4
CNS*	14	66.6	4	16.9	3	16.5	21	4.2
Entorobacter cloacae	7	51.5	2	16.4	5	32.2	14	2.9
Klebsiella oxytoca	7	63.6	-	-	4	36.4	11	2.3
Serratia marcescens	6	85.7	1	14.3	-	-	7	1.4
Stenotophomonas maltophilia	5	83.3	1	14.3	1	14.3	7	1.4
Burkhoderia cepacia	6	85.7	1	14.3	-	-	7	1.4
Enterobacter aerogenes	6	85.7	1	14.3	-	-	7	1.4
Citrobacter spp.	5	83.3	-	-	1	16.7	6	1.3
Enterococcus faecalis	2	66.6	1	33.3	-	-	3	0.6
Candida albicans	1	33.3	1	33.3	1	33.3	3	0.6
Other Corynebacterium spp.	2	66.6	1	33.3	-	-	3	0.6
Chryseobacterium indologenes	2	100	-	-	-	-	2	0.4
Achromobacter spp.	2	100	-	-	-	-	2	0.4
Gamella haemolysans	-	-	2	100	-	-	2	0.4
Leuconostoc spp.	2	100	-	-	-	-	2	0.4
Other Candida spp.	1	50	1	50	-	-	2	0.4
Streptococcus acidominimus	-	-	2	100	-	-	2	0.4
Sphingomonas paucimobilis	-	-	-	-	2	100	2	0.4
Providencia stuartii	1	100	-	-	-	-	1	0.2
Entorobacter gergoviae	1	100	-	-	-	-	1	0.2
Streptococcus agalactiae	1	100	-	-	-	-	1	0.2
Delfia acidovorans	1	100	-	-	-	-	1	0.2
Enterococcus faecium	-	-	1	100	-	-	1	0.2
Moraxella catarrhalis	1	100	-	-	-	-	1	0.2
TOTAL	409	81.8	46	9.2	45	9	500	100

CNS*: coagulase-negative staphylococci, ETA: endotracheal aspirate, BAL: bronchoalveolar lavage

Antibiotic susceptibility test was performed on all the samples with pathogenic microorganism growth, and antibiotic resistance was detected in 50.4% (252/500). The pathogen with the highest antibiotic resistance was *K. pneumonia*, and it was mostly resistant to ciprofloxacin (95%) and amikacin (93.4%) (P<0.05). The second highest antibiotic resistance was found in *P. aeruginosa* against Levofloxacin (43%) and Cefepime (38%) (P>0.05). The third highest antibiotic resistance was against Ertapenem (100%), Tobramycin (100%) and Levofloxacin (95%), found in *A. baumannii* (P<0.05). Colistin resistance of *K. pneumoniae* and *A. baumannii* isolates were 24% and 5.1%, respectively. The antibiotic resistance profiles of the most isolated pathogens are shown in Table 2.

All *C. striatum* samples were resistant to ciprofloxacin (100%), tetracycline (100%), rifampin (100%), penicillin (98.2%) and clindamycin (82%), but susceptible to vancomycin and linezolid (P<0.05) (Table 2).

The rates of antibiotic resistance of *E. coli* to ciprofloxacin, TMP-SMX, gentamicin, and piperacillintazobactam were 92%, 62%, 22%, and 14%, respectively. The production of ESBL in *E. coli* strains was 41%. The production of ESBL in *K. pneumoniae* strains (52.3%) was a bit higher than that in E. coli (41%) strains (P>0.05).

Among *Staphylococcus aureus* isolates, 22.7% were methicillin-resistant (MRSA). MRSA isolates were 100% sensitive to vancomycin and teicoplanin (P<0.05).

The antimicrobial resistance results of the predominant organisms were investigated by age groups. Tobramycin-resistant *E. coli* and Colistin-resistant *A. baumannii* rates were highest between 85-99 years of age (P<0.05). Antimicrobial resistance results for the predominant organisms by age group are shown in Table 3.

Table 2: The antibiotic resistance profiles of the most isolated six pathogens

%	Klebsiella pneumoniae (n:127)	Pseudomonas aeruginosa (n:112)	Acinetobacter baumannii (n:51)	Corynebacterium striatum (n:37)	Escherichia coli (n:32)	Staphylococcus aureus (n:32)	P-value
AK	77.1*	6	79	0	4	4	0.03
AX	-	-	-	-	74	-	NA
AMC	93.4	-	-	0	-	-	NA
AM	100	-	-	0	92.5	-	0.73
SAM	97	-	-	-	65.3	-	0.46
FEP	92.3	36.2	-	-	65.3	-	0.54
CAZ	92.3	36	-	-	63	-	0.67
CRO	93.4	-		-	78	-	0.63
CXM	93.4	-		-	85	-	0.60
CIP	95*	34.2	95	100*	92.5	4	0.02
DA	-	-	-	74.5	-	19.2	0.57
CT	23	5.3	5.1	-	0	-	0.42
DAP	-	-	-	14.2	-	-	NA
E	-	-	-	25	-	23	0.73
ETP	77	-	100*	-	0	-	0.01
FF	-	-	-	0	0	0	0.01
FA	-	-	-	0	-	11.5	0.34
CN	80.4	16	89.3	82.2*	22.2	8	0.04
IPM	61.1	43	90.4	-	-	-	0.62
LEV	91.3	43.2	95*	14.2	92.5	4	0.02
LNZ	-	-	-	0	-	-	NA
MEM	64	34.5	91	-	0	-	0.65
MXF	-	-	-	0	-	4	0.31
OX	-	-	-	0	-	31	0.52
Р	-	-	-	98.2*	-	85	0.03
TPZ	87	35.3	-	-	15	-	0.72
RA	-	-	-	100*	-	5.2	0.03
TE	55	-	-	100*	-	27	0.04
TOB	-	-	100*	-	-	-	0.02
SXT	83	-	77.3	33.3	63	11.5	0.47
TGC	-	-	7.1	-	-	-	NA
VA	-	-	-	0	-	-	NA

AK: Amikacin, AX: Amoxicillin, AMC: Amoxicillin/ Clavulanic acid, AM: Ampicillin, SAM: Ampicillin/Sulbactam, FEP: Cefepime, CAZ: Ceftazidime, CRO: Ceftriaxone, CXM: Cefuroxime, CIP: Ciprofloxacin, DA: Clindamycin, CT: Colistin, DAP: Daptomycin, E: Erythromycin, ETP: Etapenem, FF: Fosfomycin, FA: Fusidic acid, CN: Gentamicin, IPM: İmipenem, LEV: Levofloxacin, LNZ: Linezolid, MEM: Meropenem, MXF: Moxifloxacin, OX: Oxacillin, P: Penicillin, TPZ: Piperacillin +Tazobactam, RA: Rifampin, TE: Tetracycline, TOB: Tobramycin, SXT: Trimethoprim + Sulfamethoxazole, TGC: Tigecycline, VA: Vancomycin; #P<0.05, NA: Not applicable

JOSAM

Table 3: Antimicrobial resistance results for the predominant organisms by age group

	65-74 years old					lity by age g s old	, oup	85-99 year	s old
Pathogen organisms	n R (%) S (%)		75-84 years old n R (%) S (%)			n	R (%)	S (%)	
(EUCAST criteria)		(/0)	~ (~)		(,0)	~ (///			2 (70)
Klebsiella pneumoniae	38			48			41		
AK	50	71.4	28.6	10	74.3	25.7		86.2	13.8
AMC		96.4	3.6		91.4	8.6		93.1	6.9
AM		100	-		100	-		100	-
SAM		100	-		91.4	8.6		100	_
FEP		96.4	3.6		85.7	14.3		96.6	3.4
CAZ		96.4 96.4	3.6		88.6	14.3		93.1	3.4
CRO		96.4	3.6		88.6	11.4		96.6	3.4
CXM		96.4 96.4	3.6		88.6	11.4		96.6	3.4
CIP		96.4 96.4	3.6		91.4	8.6		96.6	3.4
			-						
CT		33.3			13.8	-		25.9	3.7
9.8ETP		78.7	14.9		77.8	15.9		74.5	13.8
CN		75	25		80	20		86.2	24
PM		65.2	13		63.9	27.9		54	3.4
LEV		92.9	3.6		88.6	8.6		93.1	3.4
MEM		69.6	21.7		67.2	24.1		54	24
TPZ		89.3	7.1		80	17.2		93.1	6.9
ΓE		82.1	17.9		77.1	22.9		89.7	6.9
SXT		52.9	11.8		66.7	8.3		43.5	4.3
Pseudomonas aeruginosa	28			38			46		
AK		10.8	89.2		8	88		11.3	82.3
FEP		50	50		22	78		45.2	54.8
CAZ		52.6	47.4		24	76		35.5	64.5
CIP		29.7	67.6		30	70		40.3	59.7
CT		6.5	-		2.3	6.8		7.3	-
CN		18.4	81.6		10.6	89.4		17.7	80.6
IPM		56.4	40		40.5	59.5		36.4	56.8
LEV		50	50		42	58		40.3	59.7
MEM		55.6	38.9		30.7	49.3		25.3	51.6
TPZ		52.6	47.4		20	80		37.1	62.9
Acinetobacter baumannii	11			16			24		
AK	-	88.9	11.1		100	-	- ·	80	20
CIP		100	-		100	-		100	-
CT		-	-		-	10		6.7*	6.7
ETP		_	-		100	-		100	-
CN		77.8	22.2		85.7	14.3		95	5
IPM		81.3	6.3		95.8	-		94.9	-
LEV		100	-		100	-		100	-
						-			
MEM		81.3	6.3		100	-		94.6	-
TOB		-	-		100	- 7.1		-	-
SXT		100	-	1.5	78.6	7.1		85	15
Corynebacterium striatum	11	100		15	100		11		
CIP		100	-		100	-		100	-
DA		76.5	23.5		76.2	23.8		70.6	23.5
DAP		50	-		-	-		-	-
CN		89.5	5.3		75	25		84.2	10.5
LNZ		-	100		-	100		-	94.4
P		100	-		100	-		94.4	5.6
RA		100	-		100	-		100	-
ГЕ		100	-		100	-		100	-
SXT		-	-		50	50		-	-
VA		-	100		-	100		-	100
Escherichia coli	13			6			13		
AK		9.1	90.9		-	100		-	100
AX		81.8	18.1		80	20		63.6	27.4
AM		90.9	9.1		80	20		100	-
SAM		72.7	27.3		80	20		50	50
FEP		54.5	45.5		40	40		90	10
CAZ		63.6	27.3		40	60		72.7	9.1
CRO		63.6	36.4		60	40		100	-
CXM		81.8	18.1		60	40		100	-
CIP		81.8	9.1		100	-		100	-
CT		-	20		-	33.3		-	- 11.1
	1	-	92.9		-	100		-	100
			-		-	-		-	100
ETP		-						- 18.1	81.8
ETP FF		- 27 3							01.0
ETP FF CN		27.3	72.7		20	80			100
ETP FF CN IMP		27.3 -	72.7 92.9		20	80 100		-	100
ETP FF CN IMP LEV		27.3 - 81.8	72.7 92.9 9.1		20 - 100	80 100 -		- 100	-
ETP FF CN IMP LEV MEM		27.3 - 81.8 -	72.7 92.9 9.1 92.3		20 - 100 -	80 100 - 100		- 100 -	- 100
ETP FF CN IMP LEV MEM TPZ		27.3 - 81.8	72.7 92.9 9.1 92.3 63.6		20 - 100 - 20	80 100 - 100 40		- 100 - 9.1	- 100 72.7
ETP FF CN IMP LEV MEM TPZ TOB		27.3 - 81.8 - 18.1	72.7 92.9 9.1 92.3 63.6		20 - 100 - 20 -	80 100 - 100 40		- 100 - 9.1 100*	- 100 72.7 -
ETP FF CN IMP LEV MEM TPZ TOB SXT		27.3 - 81.8 - 18.1 - 63.6	72.7 92.9 9.1 92.3 63.6 - 36.4		20 - 100 - 20 - 80	80 100 - 100 40 - 20		- 9.1 100* 54.5	- 100 72.7 - 45.5
ETP FF CN IMP LEV MEM TPZ TOB SXT TGC	-	27.3 - 81.8 - 18.1	72.7 92.9 9.1 92.3 63.6		20 - 100 - 20 -	80 100 - 100 40		- 9.1 100* 54.5	- 100 72.7 -
ETP FF CN MP EV MEM IPZ TOB SXT TGC Staphylococcus aureus	5	27.3 - 81.8 - 18.1 - 63.6 -	72.7 92.9 9.1 92.3 63.6 - 36.4 50	16	20 - 100 - 20 - 80 -	80 100 - 100 40 - 20 -	11	- 9.1 100* 54.5	- 100 72.7 - 45.5 -
ETP FF CN MP LEV MEM FPZ TOB SXT TGC Staphylococcus aureus AK	5	27.3 - 81.8 - 18.1 - 63.6 -	72.7 92.9 9.1 92.3 63.6 - 36.4 50	16	20 - 100 - 20 - 80 - 7.7	80 100 - 100 40 - 20 - 92.3	11	- 100 - 9.1 100* 54.5 -	- 100 72.7 - 45.5 - 100
ETP FF CN IMP LEV MEM TPZ TOB SXT TGC SSAT GCC Staphylococcus aureus AK CIP	5	27.3 - 81.8 - 18.1 - 63.6 -	72.7 92.9 9.1 92.3 63.6 - 36.4 50	16	20 - 100 - 20 - 80 - 7.7 7.7	80 100 - 100 40 - 20 - - 92.3 92.3	11	- 100 - 9.1 100* 54.5 -	- 100 72.7 - 45.5 - 100 100
ETP FF CN MP LEV MEM TPZ FOB SXT FGC Staphylococcus aureus AK CIP DA	5	27.3 81.8 18.1 - 63.6 - 25	72.7 92.9 9.1 92.3 63.6 - 36.4 50 100 75	16	20 - 100 - 20 - 80 - 7.7 7.7 23.1	80 100 - 100 40 - 20 - 92.3 92.3 76.9	11	- 100 - 9.1 100* 54.5 - - - 11.1	- 100 72.7 - 45.5 - 100 100 88.9
ETP FF CN IMP LEV MEM TPZ TOB SXT TGC Staphylococcus aureus AK CIP DA DAP	5	27.3 81.8 - 18.1 - 63.6 - - 25 -	72.7 92.9 9.1 92.3 63.6 - 36.4 50 100 100 75 100	16	20 - 100 - 20 - 80 - 7.7 7.7 23.1 -	80 100 - 100 40 - 20 - 92.3 92.3 76.9 100	11	- 9.1 100* 54.5 - - 11.1	- 100 72.7 - 45.5 - 100 100 88.9 100
ETP FF CN IMP LEV MEM TPZ TOB SXT TOB SXT TGC Staphylococcus aureus AK CIP DA DA DA E	5	27.3 - 81.8 - 18.1 - 63.6 - - 25 - 50	72.7 92.9 9.1 92.3 63.6 - 36.4 50 100 100 75 100 50	16	20 - 100 - 20 - 80 - 7.7 7.7 23.1 - 23.1	80 100 - 100 40 - 20 - 92.3 92.3 76.9 100 76.9	11	- 100 - 9.1 100* 54.5 - - 11.1 - 11.1	- 100 72.7 - 45.5 - 100 100 88.9 100 88.9
ETP FF CN MP LEV MEM FPZ FOB SXT FGC SXT FGC Staphylococcus aureus AK CIP DA DAP E FF	5	27.3 81.8 18.1 - 63.6 - - 50 -	$\begin{array}{c} 72.7\\ 92.9\\ 9.1\\ 92.3\\ 63.6\\ -\\ 36.4\\ 50\\ \hline \\ 100\\ 100\\ 75\\ 100\\ 50\\ 100\\ \end{array}$	16	20 - 100 - 80 - 7.7 7.7 23.1 - 23.1	80 100 - 100 40 - 20 - - 92.3 92.3 76.9 100 76.9 100	11	- 9.1 100* 54.5 - - 11.1 - 11.1	- 100 72.7 - 45.5 - 100 100 88.9 100 88.9 100
ETP FF CN MP LEV MEM PPZ FOB SXT FGC Staphylococcus aureus AK CIP DA DA DA E E FF FA	5	27.3 - 81.8 - 18.1 - 63.6 - - 25 - 50	$\begin{array}{c} 72.7\\ 92.9\\ 9.1\\ 92.3\\ 63.6\\ -\\ 36.4\\ 50\\ \hline \\ 100\\ 100\\ 75\\ 100\\ 50\\ 100\\ 100\\ 100\\ 100\\ \hline \end{array}$	16	20 - 100 - 20 - 80 - 23.1 - 23.1 - 15.4	80 100 - 100 40 - 20 - 92.3 92.3 76.9 100 76.9	11	- 100 - 9.1 100* 54.5 - - 11.1 - 11.1	- 100 72.7 - 45.5 - 100 100 88.9 100 88.9 100 88.9
ETP FF CN MP LEV MEM PPZ FOB SXT FGC Staphylococcus aureus AK CIP DA DA DA E E FF FA	5	27.3 81.8 18.1 - 63.6 - - 50 -	$\begin{array}{c} 72.7\\ 92.9\\ 9.1\\ 92.3\\ 63.6\\ -\\ 36.4\\ 50\\ \hline \\ 100\\ 100\\ 75\\ 100\\ 50\\ 100\\ \end{array}$	16	20 - 100 - 80 - 7.7 7.7 23.1 - 23.1	80 100 - 100 40 - 20 - - 92.3 92.3 76.9 100 76.9 100	11	- 9.1 100* 54.5 - - 11.1 - 11.1	- 100 72.7 - 45.5 - 100 100 88.9 100 88.9 100
ETP FF CN MP LEV MEM PZ TOB SXT FOB SXT FGC Staphylococcus aureus AK CIP DA DA DA DA DA E FF FA CN	5	27.3 81.8 18.1 - 63.6 - - - 50 - -	$\begin{array}{c} 72.7\\ 92.9\\ 9.1\\ 92.3\\ 63.6\\ -\\ 36.4\\ 50\\ \hline \\ 100\\ 100\\ 75\\ 100\\ 50\\ 100\\ 100\\ 100\\ 100\\ \hline \end{array}$	16	20 - 100 - 20 - 80 - 23.1 - 23.1 - 15.4	80 100 - 100 40 - 20 - 92.3 76.9 100 76.9 100 84.6	11	- 9.1 100* 54.5 - - 11.1 - 11.1 - 11.1	- 100 72.7 - 45.5 - 100 100 88.9 100 88.9 100 88.9
ETP FF CN MP LEV MEM FPZ TOB SXT TOG SXT TGC Staphylococcus aureus AK CIP AK CIP DA DA E E FF FA CN CN LEV	5	27.3 81.8 - 18.1 - - - - - - - - - - - - -	$\begin{array}{c} 72.7\\ 92.9\\ 9.1\\ 92.3\\ 63.6\\ -\\ 36.4\\ 50\\ \hline \\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\ \end{array}$	16	20 - 100 - 20 - 80 - 7.7 7.7 23.1 - 15.4 15.4	80 100 - 100 40 - 20 - 92.3 76.9 100 76.9 100 76.9 100 84.6 84.6	11	- 9.1 100* 54.5 - - 11.1 - 11.1 - 11.1	- 100 72.7 - 45.5 - 100 88.9 100 88.9 100 88.9 100 88.9 100
ETP FF CN MP LEV MEM TPZ TOB SXT COB SXT COB SXT COC Staphylococcus aureus AK CIP DA AK CIP DA E E FF FA CN LEV LNZ	5	27.3 81.8 - 18.1 - - - - - - - - - - - - -	$\begin{array}{c} 72.7\\ 92.9\\ 9.1\\ 92.3\\ 63.6\\ -\\ 36.4\\ 50\\ \hline \\ 100\\ 100\\ 100\\ 50\\ 100\\ 100\\ 100\\ 100$	16	20 - 100 - 20 - 80 - - 23.1 - 23.1 - 15.4 15.4 7.7 -	80 100 - 100 40 - 20 - 92.3 92.3 76.9 100 76.9 100 84.6 84.6 84.6 92.3	11	- 100 - 9.1 100* 54.5 - - - 11.1 - 11.1 - 11.1 - - - -	- 100 72.7 - 45.5 - 100 88.9 100 88.9 100 88.9 100 88.9 100 88.9 100
ETP FF CN MP LEV MEM PZ TOB SXT ST SXT ST SXT ST SXT ST SXT ST SXT ST SXT ST SXT ST SXT ST SXT ST SXT ST SXT ST SXT ST SXT ST SXT ST ST ST ST ST ST ST ST ST ST ST ST ST	5	27.3 81.8 - 18.1 - - - - - - - - - - - -	$\begin{array}{c} 72.7\\ 92.9\\ 9.1\\ 92.3\\ 63.6\\ \hline \\ 36.4\\ 50\\ \hline \\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100$	16	20 - 20 - 20 - 80 - 7.7 7.7 23.1 - 15.4 15.4 15.4 - 7.7 - 7.7 - 7.7 - 7.7 - - - - - - - - - - - - -	80 100 - 100 40 - 20 - 92.3 76.9 100 76.9 100 84.6 84.6 84.6 84.6 92.3 100 92.3	11	- 100 - 9.1 100* 54.5 - - 11.1 - 11.1 - 11.1 - 11.1 - - - - -	- 100 72.7 - 45.5 - 100 100 88.9 100 88.9 100 88.9 100 88.9 100 100 100 100 100 100 100 10
ETP FF CN MP LEV MEM PZ TOB SXT TGC Staphylococcus aureus AK CIP DA DA DA E FF FF FA CN LEV LNZ MXF OX	5	27.3 81.8 - 18.1 - - - - - - - - - - - - -	$\begin{array}{c} 72.7\\ 92.9\\ 9.1\\ 92.3\\ 63.6\\ -\\ 36.4\\ 50\\ \hline \\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100$	16	20 - 20 - 20 - - 20 - - - - - - - - - - - - -	80 100 - 100 40 - 20 - 92.3 76.9 100 76.9 100 76.9 100 84.6 84.6 92.3 100 92.3 69.2	11	- 100 - 9.1 100* 54.5 - - 11.1 - 11.1 - 11.1 - 33.3	- 100 72.7 - 45.5 - 100 100 88.9 100 88.9 100 88.9 100 88.9 100 08.9 100 08.9 100 06.7
ETP FF CN MP LEV MEM FPZ TOB SXT TGC Staphylococcus aureus AK CIP DA E E FF FA CN LEV LNZ MXF DX P	5	27.3 81.8 - 18.1 - 63.6 - - - - - - - - - - - - -	$\begin{array}{c} 72.7\\ 92.9\\ 9.1\\ 92.3\\ 63.6\\ -\\ 36.4\\ 50\\ \hline \\ 100\\ 100\\ 75\\ 100\\ 50\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100$	16	20 - 20 - 80 - 7.7 23.1 - 15.4 15.4 7.7 7.7 30.8 84.6	80 100 - 100 40 - 20 - 92.3 76.9 100 84.6 84.6 84.6 92.3 100 92.3 100 92.3 69.2 15.14	11	- 100 - 9.1 100* 54.5 - - 11.1 - 11.1 - 11.1 - - - - - 33.3 100	- 100 72.7 - 45.5 - 100 100 88.9 100 88.9 100 88.9 100 88.9 100 100 100 100 100
ETP FF CN MP LEV MEM IPZ TOB SXT TGC Staphylococcus aureus AK CIP DA DA DA DA DA E FF FA CN LEV LNZ MXF OX P RA	5	27.3 81.8 - 18.1 - - - - - - - - - - - - -	$\begin{array}{c} 72.7\\ 92.9\\ 9.1\\ 92.3\\ 63.6\\ -\\ 36.4\\ 50\\ \hline \\ 100\\ 100\\ 75\\ 100\\ 50\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100$	16	20 - 20 - 80 - 7.7 23.1 - 15.4 15.4 15.4 15.4 - 7.7 - 7.7 30.8 84.6 10	80 100 - 100 40 - 20 - 92.3 76.9 100 76.9 100 84.6 84.6 92.3 100 92.3 69.2 15.14 -	11	- 100 - 9.1 100* 54.5 - - - 11.1 - 11.1 - 11.1 - - - - - - -	- 100 72.7 - 45.5 - 100 100 88.9 100 88.9 100 88.9 100 88.9 100 88.9 100 08.6 - - - - - - - - - - - - -
ETP FF CN IMP LEV MEM TPZ TOB SXT TGC Staphylococcus aureus Staphylococcus aureus DA DA DA DA DA DA DA DA CN E FF FA CN LEV LNZ MXF OX P RA TEL	5	27.3 81.8 - 18.1 - - - - - - - - - - - - -	$\begin{array}{c} 72.7\\ 92.9\\ 9.1\\ 92.3\\ 63.6\\ \hline \\ 36.4\\ 50\\ \hline \\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100$	16	20 - 20 - 80 - - 23.1 - 23.1 - 23.1 - 15.4 15.4 15.4 7.7 - 7.7 30.8 84.6 10	80 100 - 100 40 - 20 - 92.3 76.9 100 76.9 100 76.9 100 84.6 84.6 84.6 92.3 100 92.3 69.2 15.14 - 100 -	11	- 100 - 9.1 100* 54.5 - - 11.1 - 11.1 - 11.1 - - - - - - - -	- 100 72.7 - 45.5 - 100 88.9 100 88.9 100 88.9 100 88.9 100 88.9 100 100 66.7 - - 100
ETP ETP ETP ETP ETP ETP CN MEM MEM TPZ TOB SXT TGC Staphylococcus aureus AK CO CDP DA DAP E E E E E FF FA CN LEV LNZ MXF CN LEV LNZ MXF OX P RA TEL TE SXT	5	27.3 81.8 - 18.1 - - - - - - - - - - - - -	$\begin{array}{c} 72.7\\ 92.9\\ 9.1\\ 92.3\\ 63.6\\ -\\ 36.4\\ 50\\ \hline \\ 100\\ 100\\ 75\\ 100\\ 50\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100$	16	20 - 20 - 80 - 7.7 23.1 - 15.4 15.4 15.4 15.4 - 7.7 - 7.7 30.8 84.6 10	80 100 - 100 40 - 20 - 92.3 76.9 100 76.9 100 84.6 84.6 92.3 100 92.3 69.2 15.14 -	11	- 100 - 9.1 100* 54.5 - - - 11.1 - 11.1 - 11.1 - - - - - - -	- 100 72.7 - 45.5 - 100 100 88.9 100 88.9 100 88.9 100 88.9 100 88.9 100 08.6 - - - - - - - - - - - - -

S: susceptible, R: resistant, *P<0.05, $^{\rm a}$ Antimicrobial resistance was presented as % S and % R

Discussion

Respiratory tract infections are the most common diseases in the elderly and age is a major risk factor for both occurrence and severity of respiratory tract infections. There is insufficient data on the distribution and antimicrobial susceptibility rates of bacterial pathogens that cause respiratory tract infections. Therefore, determining common pathogens and their antimicrobial resistance profiles is crucial. In our study, the most isolated pathogens were Gram-negative bacteria (68%). Premalatha et al. [9] investigated 110 geriatric patients (>65 years) with lower respiratory tract infections and reported 60% Gram-negative bacilli and 9.1% Gram-positive cocci. K. pneumoniae (36.8%) was the most frequent pathogen, followed by P. aeruginosa (22.3%) and A. baumannii (11.8%). In the randomized study by Khattab et al. [10], K. pneumoniae, P. aeroginosa and Acinetobacter spp. were the most common organisms, followed by Methicillin-resistant Staphylococcus aureus and E. coli in lower respiratory tract infections. In the present study, in line with literature, the most isolated pathogens were K. pneumoniae, P. aeruginosa, A. baumannii, C. striatum, E. coli and S. aureus in geriatric patients with respiratory tract infections [9-11]. Moreover, above 90% of K. pneumoniae, P. aeruginosa and A. baumannii positive patients were hospitalized in the intensive care units. The most common nosocomial pathogens in respiratory tract infections are seen among intensive care unit patients and in geriatric hospitals [10-12].

Antibiotic resistance is an important health problem all over the world. It is known that long-term hospitalization and use of antibiotics increase the risk of emergence of multi-resistant microorganisms. Multidrug resistant Gram-negative bacteria studies have focused on K. pneumoniae, E. coli (ESBL, carbapenemase), A. baumannii and P. aeruginosa. In our study, K. pneumoniae (52%) was the most common pathogen and a potent ESBL producer and had the highest antibiotic resistance. In many studies, K. pneumoniae was the predominant ESBL producing organism, similar to our study [10-12]. Mu et al. [12] reported that 39 strains (31%) out of the total 126 isolates of K. pneumoniae were ESBL producers. K. pneumoniae and E. coli were the second highest ESBL producer strains with 41%. Lin et al. [13] investigated the ESBL producing Enterobacterales isolates in geriatric patients in respiratory care wards. They found that the prevalence of ESBL-producing isolates of K. pneumoniae and E. coli. were 69.7% and 39.5%, respectively. The studies suggest that the prevalence of ESBL worldwide in both E. coli and K. pneumoniae is markedly increasing and the risk factors for ESBL producing are exposure to antibiotic therapy, age, and length of hospitalization [14-16].

According to the results of National Antimicrobial Resistance Surveillance 2016 data in Turkey [17], multi-drug resistance was calculated as 83.5% in invasive *Acinetobacter* spp. isolates, and colistin resistance was 6.7%. In our study, carbapenem resistance was around 93% and colistin resistance was lower than the country average (5.1%) among *A. baumannii* isolates. Altay et al. [18] investigated the etiologic agents and their antimicrobial resistances in patients with respiratory tract infections in Turkey and found that the carbapenem resistance was around 40% among *K. pneumoniae* isolates. According to the results of surveillance in 2016 in Turkey [17], multi-drug

resistance was 46.1% in invasive *K pneumoniae* isolates, and carbapenem resistance was 40%. Our results were higher compared to those in the literature, with 65% carbapenem resistance in *K. pneumoniae* isolates.

Corynebacterium striatum has been increasingly reported as an infectious agent in patients with long-term hospitalization. Formerly, it was susceptible to many drugs, but it has recently demonstrated high-level resistance to antibiotics such as macrolides, aminoglycosides etc. [19]. The increase in antimicrobial resistance of C. striatum is a great concern. Asgin et al. [20] investigated antimicrobial resistance and molecular epidemiology of 81 C. striatum strains and they reported that all C. striatum strains were resistant to penicillin, cefotaxime, ciprofloxacin, and tetracycline, but susceptible to vancomycin and linezolid. Similarly, in the present study, C. striatum showed resistance against most used antibiotics. All C. striatum samples were resistant to ciprofloxacin, tetracycline, rifampin, and penicillin, but susceptible to vancomycin and linezolid. Therefore, according to our antibiotic susceptibilities results, linezolid and vancomycin may be selected for the treatment of C. striatum infections.

One of the most well-known cases of antimicrobial resistance, Methicillin resistance in Staphylococcus aureus (MRSA), has been associated with high mortality rates every year [21]. According to National Antimicrobial Resistance Surveillance System 2016 data, MRSA in S. aureus isolates rate was 23.6% in Turkey [17]. EARS-Net 2016 [22] reported that the average rate of MRSA in S. aureus isolates is 13.7% in the European Union countries. Akgün and Sayıner [23] investigated 320 coagulase-positive S. aureus which were cultured from patients hospitalized in the intensive care unit and reported that the rate of MRSA in S. aureus isolates was 20.9% in Turkey. Khattab et al. [10] isolated 8.1% MRSA among the total isolates. They were 100% sensitive to vancomycin and teicoplanin. The present study agrees with the literature: Our rate of MRSA isolates was 22.7% and MRSA isolates were 100% sensitive to vancomycin and teicoplanin [9, 10, 13].

Age was significantly associated with differences in antimicrobial resistance for many pathogenic organisms [25, 26]. Adam et al. [26] investigated the association between age groups (children, adults, and the elderly) and antimicrobial resistance in the most identified pathogens. They reported that resistance rates are often higher among the elderly. In the present study, antimicrobial resistance rates were higher in patients >85 years of age. This may be associated with increased exposure to antimicrobial resistant organisms in long-term care facilities and frequent hospitalizations or high rate of multidrug resistance.

In the coming years, compared to non-resistant bacteria, resistant forms are expected to cause a double risk of developing a severe infections and triple risk of mortality [24].

Limitations

There are some limitations in this study. First, because this is a retrospective single-center study based on laboratory data, the data on the clinical findings and treatments of patients are not available. Second, the reference method for antibiotic susceptibility, the agar dilution test could not be performed.

Conclusion

The most encountered pathogens were *K. pneumoniae*, *P. aeruginosa*, *A. baumannii*, *C. striatum*, *E. coli* and *S. aureus* in respiratory tract samples in geriatric patients. Above 90% of *K. pneumoniae*, *P. aeruginosa* and *A. baumannii* positive geriatric patients were hospitalized in the intensive care units. The antimicrobial resistance rates were higher in patients above 85 years of age. Vancomycin and teicoplanin were the most effective antibiotics against MRSA. It is thought that the results will be useful in the preparation of treatment protocols and in guiding physicians about the correct use of antibiotics. The resistance profiles should be monitored regularly through active surveillance in geriatric patients.

References

- World Health Organisation. Definition of an older or elderly person. Available from: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health Accessed: April 5, 2021.
- Cagatay AA, Tufan F, Hindilerden F, Aydin S, Elcioglu OC, Karadeniz A, et al. The causes of acute fever requiring hospitalization in geriatric patients: comparison of infectious and noninfectious etiology. J Aging Res. 2010;380892.
- Kurtaran B, Kuscu F, Korkmaz P, Ozdemir B, Inan D, Oztoprak, et al. A snapshot of geriatric infections in Turkey: ratio of geriatric inpatients in hospitals and evaluation of their infectious diseases: A multicenter point prevalence study. Int J Infect Dis. 2020;100:337-42.
- Ieven M, Coenen S, Loens K, Lammens C, Coenjaerts F, Vanderstraeten A, et al. Aetiology of lower respiratory tract infection in adults in primary care: a prospective study in 11 European countries. Clin Microbiol Infect. 2018;24(11):1158-63.
- Troeger C, Forouzanfar M, Rao PC, Khalil I, Brown A, Swartz S, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(11):1133-61.
- Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial resistant pathogens associated with health care associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1-14.
- Tacconelli E, Pezzani MD. Public health burden of antimicrobial resistance in Europe. Lancet Infect Dis. 2019;19(1):4-6.
- EUCAST European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0-10.1. http://www.eucast.org/ast_of_bacteria/previous_versions_of_documents/ Accessed: Feb 20, 2021.
- Premalatha E, Sharavanan TKV, Jayalakshmi GA. Study on bacterial profile of lower respiratory tract infections in geriatric population. Int J Pure App Biosci. 2014;2(4):161-5.
- Khattab A, Said A, Raafat H, Osman N. Study of the pattern of respiratory infections in elderly patients at Ain Shams University hospitals. Egypt J Bronchol. 2010;4(2):111-23.
- 11. Weiner-Lastinger LM, Abner S, Edwards JR, Kallen AJ, Karlsson M, Magill S, et al. Antimicrobialresistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015–2017. Infect Control Hosp Epidemiol. 2020;41(1):1-18.
- 12. Mu XL, He LX, Zhou ZY, Zhou CM, Jia ML, Ni CM, et al. Surveillance of Lower Respiratory Tract Infection of ESBL-producing Strains and Analysis of Risk Factors for Acquisition. Chin J Nosocomiol. 2002:2.
- 13. Lin, HC, Lai LA, Wu JY, Su YM, Chang SP, Hsueh YM. Risk factors for acquiring extended-spectrum β-lactamase-producing Enterobacteriaceae in geriatric patients with multiple comorbidities in respiratory care wards. Geriatr Gerontol Int. 2013;13(3):663-71.
- 14. Rossi F, Baquero F, Hsueh PR, Paterson DL, Bochicchio GV, Snyder TA, et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART. J Antimicrob Chemother. 2006;58:205-10.
- 15. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005– 2007: results from the SMART study. Int J Antimicrob Agents. 2009;34:585-8.
- 16. Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dej-sirilert S, Mundy LM. Risk factors for and outcomes of healthcare-associated infection due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae in Thailand. Infect Control Hosp Epidemiol. 2007;28:873-6.
- 17. UAMDSS (Ulusal Antimikrobiyal Direnç Surveyans Sistemi), 2016, Public Health Institution, Ministry of Health, Ankara. http://uamdss.thsk.gov.tr Accessed: April 10, 2021.
- Kocak AA, Yayla B, Guclu AU, Mirza HC, İstar EH, Alıskan HE et al. Adana'da Evaluation of Respiratory Pathogens Isolated in a University Hospital in Adana and Their Antibiotic Resistance Profiles. Turk Mikrob Cem Derg. 2019;49(4):226-32.
- Suh JW, Ju Y, Lee CK, Sohn JW, Kim MJ, Yoon YK. Molecular epidemiology and clinical significance of Corynebacterium striatum isolated from clinical specimens. Infect Drug Resist. 2019;4:161-71.
- Asgin N, Otlu B. Antimicrobial Resistance and Molecular Epidemiology of Corynebacterium striatum Isolated in a Tertiary Hospital in Turkey. Pathogens. 2020;9(2):136.
- 21.Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PLoS One. 2017;12:e0189621.
- 22. Antimicrobial resistance in Europe 2016. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2017.
- 23. Akgun S, Sayiner HS. Using multiplex PCR as a diagnostic tool to detect methicillin resistant Staphylococcus aureus. J Surg Med. 2018;2(3):215-7.
- 24. Cecchini M, Langer J, Slawomirski L Antimicrobial Resistance in G7 Countries and Beyond: economic issues, policies and options for action, 2015. Available from: https://www.oecd.org/els/healthsystems/Antimicrobial-Resistance-in-G7-Countries-and-Beyond.pdf. Accessed: April 6, 2021.
- 25. Denkinger CM, Grant AD, Denkinger M, Gautam S, D'Agataet EMC. Increased multi-drug resistance among the elderly on admission to the hospital a 12-year surveillance study. Arch Gerontol Geriat. 2013;56:227–30.

- 26. Adam HJ, Baxter MR, Davidson RJ, Rubinstein E, Fanella S, Karlowsky JA, et al. Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals. J Antimicrob Chemother. 2013;68(1):31-7
- This paper has been checked for language accuracy by JOSAM editors.
- The National Library of Medicine (NLM) citation style guide has been used in this paper.